Access cutting-edge hepatocellular carcinoma treatment through this clinical trial at a research site in Birmingham. Study-provided care at no cost to qualified participants.
Access hepatocellular carcinoma specialists in Birmingham at no cost
This study follows strict safety protocols and ethical guidelines
All study-related hepatocellular carcinoma treatment provided free
This phase II trial evaluates lenvatinib for the treatment of hepatocellular carcinoma (HCC) that has come back (recurrent) after a liver transplant. HCC is a cancer of the liver and is the second leading cause of cancer-related deaths in the world. Liver transplantation is a potentially curative treatment option for HCC, however, up to 20% of patients develop recurrent disease after liver transplantation and prognosis remains poor. Lenvatinib may stop the growth of tumor cells by blocking some
Sponsor: Emory University
Check if you qualify for this hepatocellular carcinoma clinical trial in Birmingham, AL
If you're searching for hepatocellular carcinoma treatment options in Birmingham, AL, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Birmingham research site is actively enrolling participants for this clinical trial. You'll receive care from experienced hepatocellular carcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.